-
Sorafenib, sold
under the
brand name Nexavar, is a
kinase inhibitor drug
approved for the
treatment of
primary kidney cancer (advanced
renal cell carcinoma)...
-
phase 3 randomized, open-label,
clinical trial of Pexa-Vec plus
sorafenib versus sorafenib is
being conducted on
patients with
advanced hepatocellular carcinoma...
-
people with
hepatocellular carcinoma who have been
previously treated with
sorafenib. The
approval was
based on
CELESTIAL (NCT01908426), a
randomized (2:1)...
-
therapy (IL-2, interferon),
kinase inhibitors (temsirolimus, sunitinib,
sorafenib, pazopanib) and anti-angiogenic
therapies (bevacizumab). "Clear cell carcinoma"...
-
partner at
Institutional Venture Partners (an
original Onyx backer).
Sorafenib, co-developed and co-marketed with
Bayer and sold
under the
trade name...
-
conformations of the
kinase domain as
cancer therapeutic candidates. BAY43-9006 (
Sorafenib, Nexavar) is a V600E
mutant B-Raf and C-Raf
inhibitor approved by the...
-
diastolic was
reported in the
first 24
hours after the
first treatment with
sorafenib, a VEGF
pathway inhibitor.[non-primary
source needed]
Because these drugs...
- The
molecular formula C21H16ClF3N4O3 may
refer to:
Donafenib Sorafenib This set
index page
lists chemical structure articles ****ociated with the same...
- and
various receptor tyrosine kinases. It is a
deuterated derivative of
sorafenib with
improved pharmacokinetic properties. Keam,
Susan J.; Duggan, Sean...
- months. The most
common side
effects of
Sorafenib include a hand-foot skin
reaction and diarrhea.
Sorafenib is
thought to work by
blocking growth of...
